These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 18398322)

  • 1. Aggressive blood pressure control and stroke prevention: role of calcium channel blockers.
    Papadopoulos DP; Papademetriou V
    J Hypertens; 2008 May; 26(5):844-52. PubMed ID: 18398322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety of antihypertensive therapy.
    Grossman E; Messerli FH
    Prog Cardiovasc Dis; 2006; 49(1):16-25. PubMed ID: 16867847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systolic hypertension.
    Nash DT
    Geriatrics; 2006 Dec; 61(12):22-8. PubMed ID: 17184139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium channel blockers in treatment of hypertension.
    Muntwyler J; Follath F
    Prog Cardiovasc Dis; 2001; 44(3):207-16. PubMed ID: 11727278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy in hypertension: A focus on angiotensin receptor blockers and calcium channel blockers.
    Meka N; Katragadda S; Cherian B; Arora RR
    Am J Ther; 2010; 17(1):61-7. PubMed ID: 20090431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.
    Poon IO
    Pharmacotherapy; 2008 Mar; 28(3):366-75. PubMed ID: 18294116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary and secondary prevention of stroke by antihypertensive drug treatment.
    Wang JG; Li Y
    Expert Rev Neurother; 2004 Nov; 4(6):1023-31. PubMed ID: 15853529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin 2 type 2 receptor activity and ischemic stroke severity.
    Ovbiagele B; Kidwell CS; Starkman S; Selco SL; Rajajee V; Razinia T; Saver JL
    Neurology; 2005 Sep; 65(6):851-4. PubMed ID: 16186522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockers.
    Bangalore S; Messerli FH
    Int J Clin Pract; 2006 Oct; 60(10):1281-6. PubMed ID: 16942591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin receptor blockers and secondary stroke prevention: the MOSES study.
    Dowlatshahi D; Hill MD
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):459-64. PubMed ID: 19419253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Differential therapy with calcium antagonists].
    Scholze JE
    Herz; 2003 Dec; 28(8):754-63. PubMed ID: 14689111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.